C4 Therapeutics, Inc. (CCCC) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2023-12-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2023-12-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2023-12-31..
Borrowing debt
Overview →Financial period ending 2023-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 0.00 USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 376.45M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $376.45M | (m) |
| 2023-09-30 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $333.01M | (m) |
| 2023-06-30 | (m) | (m) | $10.34M | $0.00 | (m) | (m) | $375.01M | (m) |
| 2023-03-31 | (m) | (m) | $2.29M | $8.62M | (m) | (m) | $396.04M | (m) |
| 2022-12-31 | (m) | (m) | $2.29M | $9.20M | (m) | (m) | $430.84M | (m) |
| 2022-09-30 | (m) | (m) | $2.25M | $9.05M | (m) | $313.65M | $461.44M | (m) |
| 2022-06-30 | (m) | (m) | $750.00K | $10.37M | (m) | $307.78M | $492.48M | (m) |
| 2022-03-31 | (m) | (m) | $750.00K | $10.19M | (m) | $291.17M | $515.49M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $10.77M | (m) | $309.28M | $506.76M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $10.59M | (m) | $402.07M | $507.91M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $10.41M | (m) | $465.91M | $528.42M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $10.23M | (m) | $313.48M | $374.01M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $10.05M | (m) | $371.69M | $400.14M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $9.88M | (m) | (m) | $229.13M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |